ClinicalTrials.gg
TerminatedNCT03343067Updated Nov 27, 2019Results posted

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

A Phase 3 interventional study of elagolix and estradiol/norethindrone acetate (E2/NETA) in Endometriosis, sponsored by AbbVie. Terminated at 37 sites in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated early for business reasons, not for safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 22 studies testing elagolix in Endometriosis — 2 open to participants now, 4 under way, 2 of them phase 3. elagolix · Endometriosis.

Enrollment
21st of 22
11 · median 165
Started
2017
with 1 other
Phase 3
11 of 22
none open now
Registered
12th of 22
by date
Lead sponsor
10 of 22
AbbVie

Among the 22 studies testing elagolix in Endometriosis, this one is the 21st largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 12th registered.

Endometriosis

922 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

2 of the 22 studies testing elagolix in Endometriosis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elagolix

elagolix: first FDA approval 2018 (ORILISSA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 179 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 125 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing elagolix in Endometriosis, or all of them as a file.
02

Study summary

This is a Phase 3, dose-escalation study designed to evaluate the safety and efficacy of both elagolix alone and elagolix plus estradiol/norethindrone acetate (E2/NETA) over 24 months in the management of endometriosis with associated moderate to severe pain in premenopausal women.

03

Conditions studied

  • Endometriosis

Keywords

  • Endometriosis associated pain
  • Elagolix
  • Non-menstrual pelvic pain (NMPP)
  • Dysmenorrhea (DYS)
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is a premenopausal female 18 to 49 years of age (inclusive) at the time of Screening.
  • Participant has a documented surgical diagnosis (e.g., laparoscopy or laparotomy) of endometriosis established by visualization or histology within 10 years prior to entry into Washout or Screening,
  • Participant must agree to use only those rescue analgesics permitted by the protocol during the Screening and Treatment Periods for her endometriosis-associated pain.
  • Participant must have the following documented in the e-Diary during the last 35 days prior to Study Day 1:

    1. At least 2 days of "moderate" or "severe" DYS, AND either,
    2. At least 2 days of "moderate" or "severe" NMPP and an average NMPP score of at least 1.0, OR
    3. At least 4 days of "moderate" or "severe" NMPP and an average NMPP score of at least 0.5.

Exclusion criteria

Exclusion Criteria:

  • Participant has chronic pelvic pain that is not caused by endometriosis that requires chronic analgesic therapy, which would interfere with the assessment of endometriosis-associated pain.
  • Participant is using any systemic for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over-the-counter and prescription topical, inhaled or intranasal corticosteroids are allowed.
  • Participant has a history of major depression or post-traumatic stress disorder (PTSD) within 2 years prior to screening or other major psychiatric disorder at any time
  • Participant has a history of suicide attempts or answered "yes" to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or prior to study drug dosing on Day 1.
  • Participant has any condition that would interfere with obtaining adequate dual energy x-ray absorptiometry (DXA) measurements
  • Screening DXA results of the lumbar spine (L1 - L4), femoral neck or total hip bone mineral density (BMD) corresponding to less than 2 or more standard deviations below normal (Z-score \< -2.0 for participants \< 40 years of age, T-score for participants >= 40 years of age).
  • Participant has either

    1. a newly diagnosed, medical condition that requires therapeutic intervention (e.g., new onset hypertension) that has not been stabilized 30 days prior to enrollment on Day 1 OR
    2. a clinically significant medical condition that is anticipated to required intervention during the course of study participation (e.g., anticipated major elective surgery) OR
    3. an unstable medical condition that makes the participant an unsuitable candidate for the study in the opinion of the Investigator
  • Participant has any conditions with use of E2/NETA
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Arm A

    Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24

    Drug: elagolix

  • Experimental
    Arm C

    Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24.

    Drug: elagolix · Drug: estradiol/norethindrone acetate (E2/NETA)

  • Experimental
    Arm D

    Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24.

    Drug: elagolix · Drug: estradiol/norethindrone acetate (E2/NETA)

  • Experimental
    Arm B

    Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24.

    Drug: elagolix

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Responders at Month 6 Based on DYS Pain Scale

    Proportion of responders at Month 6 based upon the scale for DYS pain scale (ranging from 0 \[none\] to 3 \[severe\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.

    Time frame: Month 6

  2. Proportion of Responders at Month 6 Based on NMPP Pain Scale

    Proportion of responders at Month 6 based upon the scale for NMPP pain scale (ranging from 0 \[none\] to 3 \[severe\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.

    Time frame: Month 6

Secondary outcomes

  1. Change From Baseline in DYS at Month 6

    The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Month 6

  2. Change From Baseline in NMPP at Month 6

    The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Month 6

  3. Change From Baseline in Dyspareunia at Month 6

    The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Month 6

  4. Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6

    The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Month 6

  5. Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6

    Based on average pill counts and assessed using the daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.

    Time frame: Month 0 (baseline), Month 6

  6. Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6

    The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window.

    Time frame: Month 6

  7. Proportion of Responders Over Time

    As assessed by change and percent change from baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  8. Proportion of Responders Over Time (Not Taking Into Consideration of Analgesic Use)

    As assessed by change and percent change from Baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  9. Change From Baseline Over Time in Monthly Average DYS Pain Score

    The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. The analysis was based on a 28-day window. If a participant prematurely discontinued during the open-label period, based on the analysis window, some data might fall into Month 4 analysis.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  10. Change From Baseline Over Time in Monthly Average NMPP Pain Score

    The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  11. Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score

    The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  12. Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS

    The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  13. Percent Change From Baseline to Each Month During the Treatment Period for DYS

    The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  14. Percent Change From Baseline to Each Month During the Treatment Period for NMPP

    The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  15. Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia

    The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  16. Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS

    The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  17. Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics

    Based on average pill counts and assessed using a daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  18. Number of Analgesic Use Responders and Non-Responders Over Time

    Based only on reduction of rescue analgesics used. Responders were defined as: * participants with no analgesic use at screening and no analgesic use added * participants with NSAID only use at screening and NSAID dose stopped, decreased, or stable (\<15% increase) and no opioid use added * participants with opioid only use at screening and opioid dose stopped, decreased, or stable (\<15% increase), opioid dose stopped and NSAID substituted (any dose), opioid dose decreased and NSAID added (any dose) * participants with NSAID + opioid use at screening and any of the following: NSAID dose stopped + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose decreased + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose stable (\< 15% increase) + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose increased by \>15% + opioid analgesic use stopped; NSAID dose increased by \>15% + opioid analgesic dose decreases.

    Time frame: Months 1, 2, 3, 4, 5, 6

  19. Patient Global Impression of Change (PGIC) Scores Over Time

    The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7).

    Time frame: Months 1, 2, 3, 4, 5, 6

  20. Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time

    The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever.

    Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

  21. Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain

    The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

    Time frame: Month 0 (baseline), Months 3, 6

  22. EHP-30 Scores Over Time: Control and Powerlessness

    The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

    Time frame: Month 0 (baseline), Months 3, 6

  23. EHP-30 Scores Over Time: Emotional Well-Being

    The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

    Time frame: Month 0 (baseline), Months 3, 6

  24. EHP-30 Scores Over Time: Social Support

    The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

    Time frame: Month 0 (baseline), Months 3, 6

  25. EHP-30 Scores Over Time: Self-Image

    The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

    Time frame: Month 0 (baseline), Months 3, 6

  26. EHP-30 Scores Over Time: Sexual Intercourse

    The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

    Time frame: Month 0 (baseline), Months 3, 6

  27. EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility

    The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

    Time frame: Month 0 (baseline), Months 3, 6

  28. EQ-5D-5L Scores Over Time: Self-Care

    The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

    Time frame: Month 0 (baseline), Months 3, 6

  29. EQ-5D-5L Scores Over Time: Usual Activities

    The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

    Time frame: Month 0 (baseline), Months 3, 6

  30. EQ-5D-5L Scores Over Time: Pain/Discomfort

    The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

    Time frame: Month 0 (baseline), Months 3, 6

  31. EQ-5D-5L Scores Over Time: Anxiety/Depression

    The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

    Time frame: Month 0 (baseline), Months 3, 6

  32. EQ-5D-5L VAS Scores Over Time: Health Today

    The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate VAS indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

    Time frame: Month 0 (baseline), Months 3, 6

  33. Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem

    Absenteeism is presented as the mean percentage of work time missed due to health problem (as reported on the WPAI:SHP), and is calculated as: 100\*number of hours of work missed due to health problem / (number of hours of work missed due to health problem + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

    Time frame: Month 0 (baseline), Month 6

  34. WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem

    Presenteeism (the extent to which health problem decreased productivity) is presented as the mean percentage of impairment while working due to health problem, and is calculated as: 100\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

    Time frame: Month 0 (baseline), Month 6

  35. WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem

    The mean percentage of overall work impairment due to health problem (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which health problem decreased productivity (%)\* \[number of hours worked / (number of hours of work missed due to health problem + number of hours worked)\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

    Time frame: Month 0 (baseline), Month 6

  36. WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem

    Activity impairment due to health problem (the extent to which health problem affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

    Time frame: Month 0 (baseline), Month 6

  37. Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time

    The 6-item ETSQ was developed to assess patient-reported satisfaction with effects on endometriosis pain, dysmenorrhea, dyspareunia, amount of bleeding tolerability and overall treatment satisfaction. The ETSQ has a 7 point response scale. The range for this scale is 0 to 36, with lower ETSQ scores reflecting lower levels of satisfaction with endometriosis treatment.

    Time frame: Month 0 (baseline), Months 3, 6

  38. PROMIS Fatigue Short Form 6a Scores Over Time

    The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue. Possible scores range from 6 to 30, 6 = not at all (no fatigue), and 30 = very much (most fatigue).

    Time frame: Month 0 (baseline), Month 6

07

Results

Posted Nov 27, 2019
Limitations and caveats
Due to early study termination at Treatment Month 6 with low subject enrollment, no clinically or statistically meaningful efficacy conclusions can be made. The study was terminated early for business reasons, not for safety concerns.

Participant flow

Open Label Period: Day 1 to Month 3
Participant flow — Open Label Period: Day 1 to Month 3
MilestoneGroup AGroup BGroup C
Started731
Completed031
Not completed700
Double Blind Period: Month 3 to Month 6
Participant flow — Double Blind Period: Month 3 to Month 6
MilestoneGroup AGroup BGroup C
Started031
Completed000
Not completed031
Withdrew: Study terminated by sponsor031

Outcome measures

PrimaryProportion of Responders at Month 6 Based on DYS Pain Scale

Proportion of responders at Month 6 based upon the scale for DYS pain scale (ranging from 0 \[none\] to 3 \[severe\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.

Time frame:
Month 6

No measurements were reported for this outcome.

PrimaryProportion of Responders at Month 6 Based on NMPP Pain Scale

Proportion of responders at Month 6 based upon the scale for NMPP pain scale (ranging from 0 \[none\] to 3 \[severe\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryChange From Baseline in DYS at Month 6

The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · score on a scale
Change From Baseline in DYS at Month 6
score on a scaleGroup AGroup BGroup C
Change From Baseline in DYS at Month 6—-0.23 ± NA—
SecondaryChange From Baseline in NMPP at Month 6

The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · score on a scale
Change From Baseline in NMPP at Month 6
score on a scaleGroup AGroup BGroup C
Change From Baseline in NMPP at Month 6—-0.13 ± 0.061—
SecondaryChange From Baseline in Dyspareunia at Month 6

The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Dyspareunia at Month 6
score on a scaleGroup AGroup BGroup C
Change From Baseline in Dyspareunia at Month 6—0.29 ± NA—
SecondaryChange From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6
score on a scaleGroup AGroup BGroup C
Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6—-1.36 ± 0.020—
SecondaryChange From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6

Based on average pill counts and assessed using the daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · pills/day
Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6
pills/dayGroup AGroup BGroup C
NSAID: Change at Month 6—0.63 ± 0.606—
Opioid: Change at Month 6—0.09 ± 0.121—
NSAID + Opioid: Change at Month 6—0.71 ± 0.485—
SecondaryPercentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6
percentage of participantsGroup AGroup BGroup C
Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6—50.0—
SecondaryProportion of Responders Over Time

As assessed by change and percent change from baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

No measurements were reported for this outcome.

SecondaryProportion of Responders Over Time (Not Taking Into Consideration of Analgesic Use)

As assessed by change and percent change from Baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6

No measurements were reported for this outcome.

SecondaryChange From Baseline Over Time in Monthly Average DYS Pain Score

The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. The analysis was based on a 28-day window. If a participant prematurely discontinued during the open-label period, based on the analysis window, some data might fall into Month 4 analysis.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · score on a scale
Change From Baseline Over Time in Monthly Average DYS Pain Score
score on a scaleGroup AGroup BGroup C
Change at Month 10.05 ± 0.655-0.04 ± NA—
Change at Month 2-0.18 ± 0.124-0.26 ± NA—
Change at Month 3-0.50 ± 0.263-0.34 ± NA—
Change at Month 4-0.69 ± NA-0.06 ± NA—
Change at Month 5—-0.16 ± 0.141—
Change at Month 6—-0.23 ± NA—
SecondaryChange From Baseline Over Time in Monthly Average NMPP Pain Score

The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · score on a scale
Change From Baseline Over Time in Monthly Average NMPP Pain Score
score on a scaleGroup AGroup BGroup C
Change at Month 1-0.13 ± 0.252-0.07 ± 0.5080.39 ± NA
Change at Month 2-0.48 ± 0.394-0.30 ± 0.1670.29 ± NA
Change at Month 3-0.70 ± 0.828-0.30 ± 0.0920.54 ± NA
Change at Month 4-1.34 ± NA-0.34 ± 0.0290.46 ± NA
Change at Month 5—-0.27 ± 0.256—
Change at Month 6—-0.13 ± 0.061—
SecondaryChange From Baseline Over Time in Monthly Average Dyspareunia Pain Score

The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · score on a scale
Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score
score on a scaleGroup AGroup BGroup C
Change at Month 1-0.50 ± 0.7410.30 ± NA-0.29 ± NA
Change at Month 2-1.44 ± 1.0710.06 ± NA-0.37 ± NA
Change at Month 3-2.20 ± NA0.07 ± 0.101-0.03 ± NA
Change at Month 4-2.23 ± NA0.09 ± 0.040-0.03 ± NA
Change at Month 5—0.09 ± 0.081—
Change at Month 6—0.29 ± NA—
SecondaryChange From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · score on a scale
Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS
score on a scaleGroup AGroup BGroup C
Change at Month 1-0.86 ± 1.975-0.89 ± 1.159-0.84 ± NA
Change at Month 2-2.40 ± 2.106-2.02 ± 0.758-1.40 ± NA
Change at Month 3-3.70 ± 3.616-1.81 ± 0.430-1.34 ± NA
Change at Month 4-6.43 ± NA-1.43 ± 1.078-1.06 ± NA
Change at Month 5—-1.40 ± 0.961—
Change at Month 6—-1.36 ± 0.020—
SecondaryPercent Change From Baseline to Each Month During the Treatment Period for DYS

The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · percent change of units on a scale
Percent Change From Baseline to Each Month During the Treatment Period for DYS
percent change of units on a scaleGroup AGroup BGroup C
Percent Change at Month 11.67 ± 109.961-7.89 ± NA—
Percent Change at Month 2-27.45 ± 17.119-75.00 ± NA—
Percent Change at Month 3-62.92 ± 24.159-85.71 ± NA—
Percent Change at Month 4-80.00 ± NA-16.67 ± NA—
Percent Change at Month 5—-40.48 ± 33.672—
Percent Change at Month 6—-57.14 ± NA—
SecondaryPercent Change From Baseline to Each Month During the Treatment Period for NMPP

The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · percentage change of units on a scale
Percent Change From Baseline to Each Month During the Treatment Period for NMPP
percentage change of units on a scaleGroup AGroup BGroup C
Percent Change at Month 1-11.81 ± 26.6774.22 ± 53.23816.07 ± NA
Percent Change at Month 2-37.53 ± 31.150-34.21 ± 18.04411.90 ± NA
Percent Change at Month 3-38.26 ± 42.319-38.03 ± 20.34322.62 ± NA
Percent Change at Month 4-71.21 ± NA-44.49 ± 20.72519.05 ± NA
Percent Change at Month 5—-28.40 ± 33.641—
Percent Change at Month 6—-17.23 ± 16.044—
SecondaryPercent Change From Baseline to Each Month During the Treatment Period for Dyspareunia

The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · percentage change of units on a scale
Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia
percentage change of units on a scaleGroup AGroup BGroup C
Percent Change at Month 10.14 ± 18.180-15.27 ± 26.791-9.52 ± NA
Percent Change at Month 26.60 ± 15.719-15.26 ± 21.840-12.38 ± NA
Percent Change at Month 360.88 ± 65.632-21.63 ± 24.719-0.95 ± NA
Percent Change at Month 4106.25 ± NA-12.67 ± 20.433-0.95 ± NA
Percent Change at Month 5—-14.86 ± 16.002—
Percent Change at Month 6—-18.08 ± 25.571—
SecondaryPercent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS

The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · percentage change of score on a scale
Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS
percentage change of score on a scaleGroup AGroup BGroup C
Percent Change at Month 1-14.10 ± 37.146-19.61 ± 35.468-11.34 ± NA
Percent Change at Month 2-37.82 ± 18.066-56.25 ± 4.507-18.99 ± NA
Percent Change at Month 3-43.98 ± 35.509-53.05 ± 13.803-18.22 ± NA
Percent Change at Month 4-70.98 ± NA-38.00 ± 31.275-14.34 ± NA
Percent Change at Month 5—-35.81 ± 9.326—
Percent Change at Month 6—-33.56 ± 11.357—
SecondaryChange From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics

Based on average pill counts and assessed using a daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · pills/day
Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics
pills/dayGroup AGroup BGroup C
NSAID: Change at Month 1-0.84 ± 0.7960.09 ± 0.388-0.67 ± NA
NSAID: Change at Month 2-1.15 ± 0.785-0.17 ± 0.8340.63 ± NA
NSAID: Change at Month 3-0.96 ± 1.030-0.43 ± 1.091-0.71 ± NA
NSAID: Change at Month 4-1.69 ± NA0.01 ± 0.845-0.63 ± NA
NSAID: Change at Month 5—0.23 ± 1.197—
NSAID: Change at Month 6—0.63 ± 0.606—
Opioid: Change at Month 10.12 ± 0.552-0.06 ± 0.099-0.43 ± NA
Opioid: Change at Month 2-0.17 ± 0.263-0.03 ± 0.049-0.51 ± NA
Opioid: Change at Month 3-0.17 ± 0.2420.02 ± 0.016-0.49 ± NA
Opioid: Change at Month 4-0.34 ± NA-0.01 ± 0.044-0.40 ± NA
Opioid: Change at Month 5—-0.05 ± 0.082—
Opioid: Change at Month 6—0.09 ± 0.121—
NSAID + Opioid: Change at Month 1-0.72 ± 1.1780.03 ± 0.436-1.10 ± NA
NSAID + Opioid: Change at Month 2-1.33 ± 0.767-0.20 ± 0.830-1.14 ± NA
NSAID + Opioid: Change at Month 3-1.13 ± 1.273-0.41 ± 1.107-1.20 ± NA
NSAID + Opioid: Change at Month 4-2.03 ± NA-0.00 ± 0.863-1.03 ± NA
NSAID + Opioid: Change at Month 5—0.18 ± 1.217—
NSAID + Opioid: Change at Month 6—0.71 ± 0.485—
SecondaryNumber of Analgesic Use Responders and Non-Responders Over Time

Based only on reduction of rescue analgesics used. Responders were defined as: * participants with no analgesic use at screening and no analgesic use added * participants with NSAID only use at screening and NSAID dose stopped, decreased, or stable (\<15% increase) and no opioid use added * participants with opioid only use at screening and opioid dose stopped, decreased, or stable (\<15% increase), opioid dose stopped and NSAID substituted (any dose), opioid dose decreased and NSAID added (any dose) * participants with NSAID + opioid use at screening and any of the following: NSAID dose stopped + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose decreased + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose stable (\< 15% increase) + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose increased by \>15% + opioid analgesic use stopped; NSAID dose increased by \>15% + opioid analgesic dose decreases.

Time frame:
Months 1, 2, 3, 4, 5, 6
Reported as:
Count of participants · Participants
Number of Analgesic Use Responders and Non-Responders Over Time
ParticipantsGroup AGroup BGroup C
Month 1: Responder521
Month 1: Non-Responder210
Month 2: Responder421
Month 2: Non-Responder110
Month 3: Responder211
Month 3: Non-Responder020
Month 4: Responder121
Month 4: Non-Responder010
Month 5: Responder020
Month 5: Non-Responder010
Month 6: Responder000
Month 6: Non-Responder020
SecondaryPatient Global Impression of Change (PGIC) Scores Over Time

The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7).

Time frame:
Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · score on a scale
Patient Global Impression of Change (PGIC) Scores Over Time
score on a scaleGroup AGroup BGroup C
Month 12.9 ± 1.352.3 ± 0.582.0 ± NA
Month 22.0 ± 0.001.3 ± 0.582.0 ± NA
Month 32.0 ± NA2.0 ± 1.005.0 ± NA
Month 4—2.0 ± 1.002.0 ± NA
Month 5—2.5 ± 0.71—
Month 6—1.0 ± NA—
SecondaryOverall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time

The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever.

Time frame:
Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Reported as:
Mean · score on a scale
Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time
score on a scaleGroup AGroup BGroup C
Baseline8.2 ± 1.799.0 ± 1.007.0 ± NA
Month 15.7 ± 3.047.7 ± 1.158.0 ± NA
Month 24.5 ± 0.712.7 ± 1.155.0 ± NA
Month 39.0 ± NA5.3 ± 2.318.0 ± NA
Month 4—3.3 ± 0.587.0 ± NA
Month 5—8.0 ± 0.00—
Month 6—4.0 ± NA—
SecondaryEndometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain
score on a scaleGroup AGroup BGroup C
Baseline59.42 ± 11.69447.73 ± 14.19359.09 ± NA
Month 338.07 ± 26.52917.42 ± 22.42238.64 ± NA
Month 6—27.27 ± NA—
SecondaryEHP-30 Scores Over Time: Control and Powerlessness

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EHP-30 Scores Over Time: Control and Powerlessness
score on a scaleGroup AGroup BGroup C
Baseline71.43 ± 19.15956.94 ± 19.69141.67 ± NA
Month 336.46 ± 32.87426.39 ± 21.38225.00 ± NA
Month 6—8.33 ± NA—
SecondaryEHP-30 Scores Over Time: Emotional Well-Being

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EHP-30 Scores Over Time: Emotional Well-Being
score on a scaleGroup AGroup BGroup C
Baseline29.76 ± 8.81550.00 ± 8.33345.83 ± NA
Month 318.75 ± 12.50023.61 ± 17.34737.50 ± NA
Month 6—25.00 ± NA—
SecondaryEHP-30 Scores Over Time: Social Support

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EHP-30 Scores Over Time: Social Support
score on a scaleGroup AGroup BGroup C
Baseline48.21 ± 21.56545.83 ± 19.09450.00 ± NA
Month 317.19 ± 11.83116.67 ± 28.86818.75 ± NA
Month 6—25.00 ± NA—
SecondaryEHP-30 Scores Over Time: Self-Image

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EHP-30 Scores Over Time: Self-Image
score on a scaleGroup AGroup BGroup C
Baseline50.00 ± 22.04836.11 ± 31.54975.00 ± NA
Month 343.75 ± 41.5978.33 ± 14.4348.33 ± NA
Month 6—16.67 ± NA—
SecondaryEHP-30 Scores Over Time: Sexual Intercourse

The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EHP-30 Scores Over Time: Sexual Intercourse
score on a scaleGroup AGroup BGroup C
Baseline70.00 ± 22.36162.50 ± 31.82060.00 ± NA
Month 345.00 ± 23.45245.00 ± 42.42660.00 ± NA
Month 6—30.00 ± NA—
SecondaryEuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility
score on a scaleGroup AGroup BGroup C
Baseline1.4 ± 0.531.0 ± 0.001.0 ± NA
Month 31.3 ± 0.501.0 ± 0.002.0 ± NA
Month 6—1.0 ± NA—
SecondaryEQ-5D-5L Scores Over Time: Self-Care

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EQ-5D-5L Scores Over Time: Self-Care
score on a scaleGroup AGroup BGroup C
Baseline1.0 ± 0.001.0 ± 0.001.0 ± NA
Month 31.0 ± 0.001.0 ± 0.001.0 ± NA
Month 6—1.0 ± NA—
SecondaryEQ-5D-5L Scores Over Time: Usual Activities

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EQ-5D-5L Scores Over Time: Usual Activities
score on a scaleGroup AGroup BGroup C
Baseline2.0 ± 0.821.3 ± 0.581.0 ± NA
Month 31.5 ± 0.581.7 ± 1.152.0 ± NA
Month 6—1.0 ± NA—
SecondaryEQ-5D-5L Scores Over Time: Pain/Discomfort

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EQ-5D-5L Scores Over Time: Pain/Discomfort
score on a scaleGroup AGroup BGroup C
Baseline2.7 ± 0.762.7 ± 0.584.0 ± NA
Month 32.0 ± 1.151.7 ± 0.583.0 ± NA
Month 6—1.0 ± NA—
SecondaryEQ-5D-5L Scores Over Time: Anxiety/Depression

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EQ-5D-5L Scores Over Time: Anxiety/Depression
score on a scaleGroup AGroup BGroup C
Baseline1.0 ± 0.001.3 ± 0.581.0 ± NA
Month 31.0 ± 0.001.0 ± 0.001.0 ± NA
Month 6—1.0 ± NA—
SecondaryEQ-5D-5L VAS Scores Over Time: Health Today

The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate VAS indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
EQ-5D-5L VAS Scores Over Time: Health Today
score on a scaleGroup AGroup BGroup C
Baseline79.7 ± 15.1653.3 ± 35.1272.0 ± NA
Month 372.8 ± 17.6385.0 ± 15.0070.0 ± NA
Month 6—94.0 ± NA—
SecondaryWork Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem

Absenteeism is presented as the mean percentage of work time missed due to health problem (as reported on the WPAI:SHP), and is calculated as: 100\*number of hours of work missed due to health problem / (number of hours of work missed due to health problem + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · percent of work time missed
Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem
percent of work time missedGroup AGroup BGroup C
Baseline0.16 ± 0.2050.08 ± 0.144—
Month 60.00 ± 0.0000.00 ± NA—
SecondaryWPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem

Presenteeism (the extent to which health problem decreased productivity) is presented as the mean percentage of impairment while working due to health problem, and is calculated as: 100\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · percent impairment while working
WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem
percent impairment while workingGroup AGroup BGroup C
Baseline0.57 ± 0.2730.53 ± 0.153—
Month 60.30 ± 0.2650.30 ± NA—
SecondaryWPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem

The mean percentage of overall work impairment due to health problem (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which health problem decreased productivity (%)\* \[number of hours worked / (number of hours of work missed due to health problem + number of hours worked)\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · percent overall work impairment
WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem
percent overall work impairmentGroup AGroup BGroup C
Baseline0.61 ± 0.3070.56 ± 0.194—
Month 60.30 ± 0.2650.30 ± NA—
SecondaryWPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem

Activity impairment due to health problem (the extent to which health problem affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · percentage impairment of activity
WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem
percentage impairment of activityGroup AGroup BGroup C
Baseline0.66 ± 0.2370.67 ± 0.0580.70 ± NA
Month 60.40 ± 0.3460.30 ± NA0.70 ± NA
SecondaryHealth Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time

The 6-item ETSQ was developed to assess patient-reported satisfaction with effects on endometriosis pain, dysmenorrhea, dyspareunia, amount of bleeding tolerability and overall treatment satisfaction. The ETSQ has a 7 point response scale. The range for this scale is 0 to 36, with lower ETSQ scores reflecting lower levels of satisfaction with endometriosis treatment.

Time frame:
Month 0 (baseline), Months 3, 6
Reported as:
Mean · score on a scale
Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time
score on a scaleGroup AGroup BGroup C
Baseline19.71 ± 4.53618.00 ± 0.00018.00 ± NA
Month 322.25 ± 9.43025.47 ± 6.65225.00 ± NA
Month 6—31.00 ± NA—
SecondaryPROMIS Fatigue Short Form 6a Scores Over Time

The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue. Possible scores range from 6 to 30, 6 = not at all (no fatigue), and 30 = very much (most fatigue).

Time frame:
Month 0 (baseline), Month 6
Reported as:
Mean · score on a scale
PROMIS Fatigue Short Form 6a Scores Over Time
score on a scaleGroup AGroup BGroup C
Baseline22.1 ± 4.1019.3 ± 6.1127.0 ± NA
Month 615.3 ± 7.7711.0 ± NA21.0 ± NA

Adverse events

Collected over From first dose of study drug up to 6 months, plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A0/7 (0%)0/7 (0%)3/7 (42.9%)
Group B0/3 (0%)0/3 (0%)3/3 (100%)
Group C0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventGroup AGroup BGroup C
ANAPHYLACTIC REACTIONImmune system disorders0/70/31/1
DRUG HYPERSENSITIVITYImmune system disorders0/70/31/1
GARDNERELLA INFECTIONInfections and infestations0/71/31/1
PELVIC PAINReproductive system and breast disorders0/71/31/1
THROAT TIGHTNESSRespiratory, thoracic and mediastinal disorders0/70/31/1
EAR DISCOMFORTEar and labyrinth disorders0/71/30/1
ABDOMINAL PAIN UPPERGastrointestinal disorders0/71/30/1
DIARRHOEAGastrointestinal disorders1/71/30/1
ORAL HERPESInfections and infestations0/71/30/1
ADNEXA UTERI PAINReproductive system and breast disorders0/71/30/1

Baseline characteristics

Age, Customized
Age, Customized(Participants)Group AGroup BGroup CTotal
20 to < 25 years1102
25 to < 30 years0101
30 to < 35 years1012
35 to < 40 years1001
40 to < 45 years3104
45 to < 50 years1001
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BGroup CTotal
Female73111
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group AGroup BGroup CTotal
Hispanic or Latino1113
Not Hispanic or Latino6208
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group AGroup BGroup CTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American2103
White5106
More than one race0112
Unknown or Not Reported0000
Dysmenorrhea (DYS) Pain Scale
Dysmenorrhea (DYS) Pain Scale(score on a scale)Group AGroup BGroup CTotal
Mean0.641 ± 0.16890.429 ± 0.10300.600 ± NA0.579 ± 0.1696
Non-Menstrual Pelvic Pain (NMPP) Pain Scale
Non-Menstrual Pelvic Pain (NMPP) Pain Scale(score on a scale)Group AGroup BGroup CTotal
Mean1.053 ± 0.45340.914 ± 0.47212.400 ± NA1.138 ± 0.5893
Dyspareunia Pain Scale
Dyspareunia Pain Scale(score on a scale)Group AGroup BGroup CTotal
Mean0.539 ± 0.90640.043 ± 0.02023.000 ± NA0.686 ± 1.1187
Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS)
Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS)(score on a scale)Group AGroup BGroup CTotal
Mean5.176 ± 1.93023.638 ± 1.56927.371 ± NA4.956 ± 1.9663

1 further baseline measures are reported on the registry.

08

Study locations

37 sites
  • Pinnacle Research Group /ID# 202016
    Anniston, Alabama 36207, United States
  • Noble Clinical Research /ID# 170628
    Tucson, Arizona 85704, United States
  • Lynn Institute of the Ozarks /ID# 165052
    Little Rock, Arkansas 72205, United States
  • SC Clinical Research /ID# 165049
    Garden Grove, California 92844, United States
  • Marvel Clinical Research /ID# 169633
    Huntington Beach, California 92647, United States
  • Health care Affiliates Medical Group /ID# 165048
    Santa Ana, California 92704, United States
  • Western States Clinical Res /ID# 169809
    Wheat Ridge, Colorado 80033-2896, United States
  • Nova Clinical Research, LLC /ID# 202227
    Bradenton, Florida 34209-4616, United States
  • Midland Florida Clinical Research Center /ID# 201327
    DeLand, Florida 32720-0920, United States
  • Southeastern Integrated Med /ID# 203109
    Gainesville, Florida 32607, United States
  • Care Partners Clinical Researc /ID# 168395
    Jacksonville, Florida 32277, United States
  • LCC Medical Research Institute /ID# 168888
    Miami, Florida 33126, United States
  • A Premier Clinical Research of Florida, LLC /ID# 201887
    Orange City, Florida 32763-2833, United States
  • GCP Clinical Research, LLC /ID# 169774
    Tampa, Florida 33609-4044, United States
  • Triple O Research Institute /ID# 201128
    West Palm Beach, Florida 33407-3100, United States
  • Bingham Memorial Hospital /ID# 170110
    Blackfoot, Idaho 83221, United States
  • Leavitt Womens Healthcare /ID# 169495
    Idaho Falls, Idaho 83404-8322, United States
  • Quad Clinical Research, LLC /ID# 168294
    Chicago, Illinois 60605, United States
  • Quad Clinical Research, LLC /ID# 170629
    Chicago, Illinois 60605, United States
  • Women's Health Care, PC /ID# 165033
    Newburgh, Indiana 47630-8940, United States
  • Delricht Research /ID# 200219
    New Orleans, Louisiana 70115, United States
  • Quad Clinical Research, LLC /ID# 200180
    Saint Louis, Missouri 63108-3204, United States
  • Montana Health Research Inst /ID# 170624
    Billings, Montana 59102, United States
  • Excel Clinical Research /ID# 170620
    Las Vegas, Nevada 89109, United States
  • Northwell health system /ID# 200162
    Manhasset, New York 11030-3816, United States
  • Radiant Research, Inc /ID# 200045
    Akron, Ohio 44311, United States
  • Central Ohio Clinical Research /ID# 170750
    Columbus, Ohio 43213-3399, United States
  • Optimed Research /ID# 167642
    Columbus, Ohio 43235, United States
  • VitaLink Research /ID# 168401
    Greenville, South Carolina 29601, United States
  • VitaLink Research /ID# 170625
    Greenville, South Carolina 29601, United States
  • Fusion Clinical Research of Spartanburg /ID# 200010
    Spartanburg, South Carolina 29301-5642, United States
  • Centex Studies, Inc /ID# 169897
    Houston, Texas 77058-2705, United States
  • America's Adv. Wellness Center /ID# 170005
    Houston, Texas 77080, United States
  • ClinRx Research, LLC /ID# 201189
    Plano, Texas 75024-5280, United States
  • Progressive Clinical Research /ID# 205565
    San Antonio, Texas 78229, United States
  • Eastern Virginia Med School /ID# 165016
    Norfolk, Virginia 23507-1627, United States
  • Seattle Reproductive Medicine /ID# 171079
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Oct 2018, 9 months.

Results were first posted in Nov 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2017
First posted
Nov 17, 2017
StartActual
Dec 27, 2017
Primary completionActual
Oct 23, 2018
CompletionActual
Oct 23, 2018
Results first posted
Nov 27, 2019
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03343067
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Dec 27, 2017
Primary completion
Oct 23, 2018
Completion
Oct 23, 2018
Results posted
Nov 27, 2019
Last update
Nov 27, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elagolix

Start the discussion